BioSpace News Archive

BioInvent International AB (“BioInvent”) (Nasdaq Stockholm:BINV) today announces it has been selected as partner of The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP), aimed at advancing the company’s program to treat blood cancers.

Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) (“APC” or the “Company”) is pleased to announce that the Supreme Court of British Columbia (the “Court”) has issued an interim order (the “Interim Order”) on January 16, 2023 in connection with the Company’s proposed Plan of Arrangement (see below).

Eargo, Inc. announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the previously announced 1-for-20 reverse stock split of the Company’s common stock.

Allogene Therapeutics, Inc. announced that it will participate in two upcoming investor conferences.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”) and its majority-owned subsidiaries Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or “Lucid Diagnostics”) today provided a strategic business update, outlining near-term strategic priorities and resource reallocation.

Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced its participation in Key Opinion Leader (KOL) event focusing on the anti-infective treatment landscape in cystic fibrosis (CF) and the Company’s Phase 2a trial of AR-501 in CF patients.

Biological Dynamics, Inc., a company developing and commercializing its proprietary ExoVerita™ platform for early disease detection and other applications, today announced Peter C. Wulff as Chief Financial Officer effective January 1, 2023.

RELIEF THERAPEUTICS Holding SA announced independent institutional review board approval for the protocol of an investigator-initiated trial to evaluate RLF-TD011 as an adjunctive treatment for patients diagnosed with cutaneous t-cell lymphoma.

Avacta Group plc, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces that AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial.

CEPI, the Coalition for Epidemic Preparedness Innovations, and Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, have signed a partnership agreement to advance the development of Vaxxas’ needle-free vaccine-patch delivery technology in a project that could end the need for frozen storage of mRNA vaccines.